[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocognitive-decline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocognitive-decline":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100567470","a-multifocal-tdcs-eeg-protocol-for-improving-symptoms-of-mild-cognitive-impairment-and-early-dementia-100567470",false,"NCT06668610","A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia","An Integrated Multifocal tDCS-EEG Protocol for Improving Cognitive and Affective Symptoms in Mild Cognitive Impairment and Early Stages of Dementia: a Crossover Double-blind Randomised Controlled Trial","MuSt-MID","Inclusion Criteria:\n\n* age between 55 and 85 years;\n* diagnosis of minor neurocognitive disorder, or major neurocognitive disorder with mild severity, according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA 2013) with a Clinical Dementia Rating Scale (CDR) of .05 or 1 (Morris, 1993);\n* right handedness.\n\nExclusion Criteria:\n\n* brain events with an acute aetiology (stroke, traumatic brain injury, neoplastic ablation);\n* psychiatric disorders (schizophrenia, psychosis, bipolar disorder) and assumption of psychotropic drugs;\n* diagnosis of moderate or severe major neurocognitive disorders (DSM-5; APA 2013) with CDR scores equal or above 2 (Morris, 1993);\n* any condition with may also hypothetically interfere with electrophysiological recording and neurostimulation (metallic implants in the brain, cochlear implant, pacemakers, or suffering from epilepsy) (Antal et al., 2017; Bikson et al., 2016).","ALL","55 Years","85 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if an integrated protocol using multifocal non invasive brain stimulation and brain recording combined with cognitive training is effective in treating cognitive and affective symptomatology in patients with mild cognitive impairment and early stages of dementia. The main questions it aims to answer are:\n\n* Does multifocal non-invasive brain stimulation reduce cognitive and affective symptoms in patients with mild cognitive impairment and early stages of dementia?\n* Do some specific factors, such as education and cognitive reserve, affect the extent of the possible outcomes achievable from the intervention?\n* Do electrophysiological measures contribute identifying responders and non-responders to the treatment? Researchers will compare real non-invasive brain stimulation to a placebo stimulation (reproducing the same feeling of stimulation without actually stimulating the brain) combined with cognitive rehabilitation on general cognition measures and depression symptoms.\n\nParticipants will\n\n* Undergo two treatment cycles (real stimulation or placebo over frontal and temporal ares of the left hemisphere) combined with cognitive training twice a week for two months.\n* Complete neuropsychological evaluations before the first rehabilitation cycle and at the end of each rehabilitation cycle.\n\nCaregivers will provide information on functional daily living activities for their relatives.",[28,29,30,31,32,33],"Mild Cognitive Impairment (MCI)","Dementia","Alzheimer Disease, Early Onset","Alzheimer Disease","Frontotemporal Degeneration (FTD)","Neurocognitive Decline",[35,36,37,38,39,40,41,42],"non invasive brain stimulation (NIBS)","transcranial direct current stimulation (tDCS)","electroencephalography (EEG)","crossover","randomised controlled trial","mild cognitive impairment","early stage dementia","multifocal brain stimulation","RECRUITING","2026-04-21",{"date":46,"type":47},"2026-04-22","ACTUAL",{"date":49,"type":47},"2024-10-01",{"date":51,"type":22},"2026-10-01",{"name":53,"class":54},"University of Campania Luigi Vanvitelli","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":17,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":69,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":55},"100632973","mistic-study-atherosclerosis-neurocognition--cardiovascular-signaling-100632973","NCT07520643","MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling","Multilevel and Interdisciplinary Assessment of Subclinical to Clinical Atherosclerosis Interactions With Neurocognitive Function and Cardiovascular System Through Endothelial and Inflammatory Cell Signalling: The MISTIC Study","MISTIC","Control Group\n\nInclusion Criteria:\n\n* Age \\>= 18 years\n* Capacity to provide informed consent\n* Documented coronary artery stenosis ≥ 50 % through peripheral vascular ultrasound imaging.Documented coronary artery stenosis ≥ 50 % through peripheral vascular ultrasound imaging.\n\nExclusion Criteria:\n\n* Prior ischemic cardiac events (e.g., myocardial infarction, unstable angina).\n* Major electrophysiological disorders.\n* History of stroke or transient ischemic attack.\n* Ongoing renal replacement therapy (dialysis).\n* Use of systemic immunosuppressive or anti-inflammatory medications (beyond low-dose aspirin).\n* Any chronic inflammatory or autoimmune disease.\n* Active infectious disease at the time of enrolment.\n* Active malignancy or cancer treatment within the past 5 years.\n\nCoronary Artery Disease Group\n\nInclusion Criteria:\n\n* Age \\>= 18 years\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Prior ischemic cardiac events (e.g., myocardial infarction, unstable angina).\n* Major electrophysiological disorders.\n* History of stroke or transient ischemic attack.\n* Ongoing renal replacement therapy (dialysis).\n* Use of systemic immunosuppressive or anti-inflammatory medications (beyond low-dose aspirin).\n* Any chronic inflammatory or autoimmune disease.\n* Active infectious disease at the time of enrolment.\n* Active malignancy or cancer treatment within the past 5 years.",true,"18 Years","80 Years",{"count":68,"type":22},1000,"6 Months","OBSERVATIONAL","The MISTIC study is a non-profit, cross-sectional clinical research project aimed at investigating the relationship between atherosclerosis and both cardiovascular and cognitive function in adult populations.\n\nAtherosclerosis is a progressive condition characterized by the accumulation of material within arterial walls, leading to vascular narrowing and impaired blood flow. While its most recognized consequences are acute events such as myocardial infarction or stroke, earlier stages of the disease, often asymptomatic, may already be associated with functional changes affecting multiple organ systems.\n\nThis study focuses on evaluating the association between vascular health and cognitive performance at a single time point. Atherosclerotic burden will be assessed using non-invasive imaging techniques, including carotid intima-media thickness and coronary calcium scoring. Cognitive performance will be measured using standardized neuropsychological tests.\n\nApproximately 1000 participants will be enrolled and divided into two groups: a control group without clinically established cardiovascular disease, and a group of patients with coronary artery disease (CAD). All participants will undergo clinical evaluation, vascular imaging, cognitive testing, and analysis of biological samples.\n\nThe primary objective is to determine whether increasing atherosclerotic burden is associated with measurable differences in cognitive and cardiovascular function. Secondary aims include identifying patterns that may help improve early detection and risk stratification of vascular disease.\n\nThe results of this study are expected to contribute to a better understanding of atherosclerosis as a systemic condition and to support the development of preventive strategies targeting early stages of vascular disease.",[73,33],"Subclinical Atherosclerotic Cardiovascular Disease",[75,33,76],"Atherosclerosis","Inflammation","NOT_YET_RECRUITING","2026-04-02",{"date":80,"type":47},"2026-04-09",{"date":82,"type":22},"2026-05-01",{"date":84,"type":22},"2030-04-30",{"name":86,"class":54},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":55},"100562855","constellations-living-lab-improving-the-care-transitions-of-older-adults-living-with-neurocognitive-disorders-100562855","NCT06608589","CONSTELLATIONS Living Lab: Improving the Care Transitions of Older Adults Living with Neurocognitive Disorders","CONSTELLATIONS Living Lab: Development, Implementation and Evaluation of a Patient-oriented Quality Improvement Program Targeting Care Transitions of Older Adults Living with Major Neurocognitive Disorders and Their Caregivers.","Study population for the evaluation of the impact of the CoMPAS+ MNCD Program on the care transitions of patients living with MNCD and their caregivers (Micro level)\n\nInclusion criteria:\n\n* Be 65 years of age or older;\n* Be living with a major neurocognitive disorder in the process of clinical evaluation or already diagnosed;\n* Reside in the socio-sanitary region of the CISSS CA;\n* Be able to consent independently to research (for users without caregivers at the beginning of their illness);\n* Reside at home or in a retirement home or in an intermediate residence or a family-type resources;\n* Consent to the research team collecting data in their medical records (FMG Electronic Medical Record (EMR) when accessible, Hospital Electronic Patient Record (EPR) when accessible, etc.).\n\nOR\n\n* Be the caregiver of a person 65 years of age and older living with a major neurocognitive disorder in the process of clinical evaluation or already diagnosed;\n* The person being cared for must reside in the socio-sanitary region of the CISSS CA;\n* Consent to the research team collecting data from the medical records of the person being cared for (FMG Electronic Medical Record (EMR) when accessible, Hospital Electronic Patient Record (EPR) when accessible, etc.);\n* Be able to consent independently to research.\n\nExclusion criteria:\n\n* Users living with major neurocognitive disorder under 65 years of age;\n* User living in a provincial long-term care facility at the time of recruitment;\n* User 65 years of age and older living with a major neurocognitive disorder, unable to consent independently to research, without a caregiver, or without a caregiver able to consent independently to research;\n* Users aged 65 and over living with a major neurocognitive disorder, residing in a territory other than that of the CISSS CA;\n* User refusing to consent to the collection of data in their medical records; OR\n* Caregiver of a user living with a major neurocognitive disorder who does not reside in the CISSS CA territory or who is not 65 years of age or does not live at home, in a retirement home or in an IR or who died before the start of the study (T=0).\n* Caregiver refusing to consent to the collection of data in the medical records of the person being cared for.\n\nStudy population for the assessment of the intention to apply best practices of CoMPAS+ MNCD workshop participants (Meso level)\n\nInclusion criteria:\n\n● Be a participant in the CoMPAS+ MNCD workshops and be part of at least one of the following categories of participants:\n\n* Health professionals working in a CISSS CA health facility or with a community organization;\n* CISSS CA decision-makers or local managers;\n* Community service representative (e.g., Alzheimer's Society, L'APPUI);\n\nExclusion criteria:\n\n* Research team members\n* Workshop facilitators\n* INESSS professionals\n* Users and partner caregivers\n* Person unable to consent\n* Person refusing to consent\n\nStudy population for the evaluation of the potential to scale-up and sustainability of the CoMPAS+ MNCD Program within the CISSS CA (Meso level)\n\nInclusion criteria\n\n● Be part of one of the following categories of actors and be involved in the implementation of the CoMPAS+ MNCD Program:\n\n* Health professionals working at the CISSS CA or in the community participating in the CoMPAS+ MNCD workshops;\n* CISSS CA decision-makers;\n* Users and partner caregivers;\n* Community service representatives (e.g., Alzheimer's Society, L'APPUI);\n* Members of the research team (except the person in charge of this component (Laetitia Bert), Alexander Cornea (research assistant), Martyne Audet (scientific coordinator), Clémence Dallaire, André Côté, Félix Pageau, Catherine Paquet);\n* Research coordinator responsible for the involvement of partner users in the conduct of the workshops (Émilie Côté);\n* INESSS professionals;\n* Workshop facilitators\n* Representative of the Ministry of Health and Social Services (MSSS).\n\nExclusion criteria\n\n* Person unable to consent;\n* A person refusing to consent;\n* Member of the research team responsible for carrying out this part of the study or by the scientific coordination of this project (Laetitia Bert, Alexander Cornea, Martyne Audet (scientific coordinator), Clémence Dallaire, André Côté, Félix Pageau, Catherine Paquet).","65 Years",{"count":96,"type":22},700,[25],"The prevalence of major neurocognitive disorders (MNCDs), particularly Alzheimer's disease, among older adults is increasing. These individuals and their caregivers often face challenges due to inefficient and poorly coordinated care transitions, negatively impacting patients, caregivers, healthcare professionals, and the healthcare system itself. To address this, the Quebec Ministry of Health and Social Services has released Phase 3 of its Ministerial Guidance on Major Neurocognitive Disorders, aiming to enhance care coordination between primary healthcare professionals and those living with MNCDs and their caregivers.\n\nQuebec's healthcare system comprises various organizations providing care and services to individuals with MNCDs. Each organization faces unique challenges hindering improvement initiatives. However, common obstacles persist: inadequate communication systems for sharing vital information, lack of access to data for measuring care transition quality, and the absence of patient\u002Fcaregiver satisfaction assessments to inform service enhancements. Additionally, organizations require support in managing change.\n\nThis need for improvement, coupled with the aspiration for a patient-centered learning health system (LHS), motivated the Institut national d'excellence en santé et services sociaux (INESSS), the Centre intégré de santé et de services sociaux de Chaudière-Appalaches (CISSS CA), and the research team to collaborate on adapting a proven continuous improvement program: the CoMPAS+ MNCD Program.\n\nThe Program will involve reflecting on best practices and identifying local challenges within participating Family Medicine Groups (FMGs) to propose and implement solutions. The CONSTELLATIONS Living Lab project has been tasked with co-developing, implementing, and evaluating the Program's impact on care transitions over two years. These findings will inform decision-makers and stakeholders about the Program's adaptability to the Chaudière-Appalaches region, guiding local and provincial decision-makers on healthcare system improvements and emphasizing the importance of supporting an LHS.",[31,29,33],[101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120],"Quality improvement","Older adults","Learning Health Systems","Implementation science","Health care utilisation","Knowledge translation","Context adaptation","Care transitions","Burden of care","Emergency Department","Home care","Family medicine","Data management","Patient-oriented research","Participatory research","Living Lab","Health services","Neurocognitive disorders","Sustainability","Scale-up","2024-10-09",{"date":123,"type":47},"2024-10-15",{"date":125,"type":47},"2023-03-14",{"date":127,"type":22},"2026-04-30",{"name":129,"class":54},"Laval University"]